Drug Trial Radar · NCT05405660
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Jun 28, 2022
Primary completion
Jun 12, 2024
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Celldex TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.
Conditions
- Chronic Inducible Urticaria
Interventions
barzolvolimabBiological
Subcutaneous Administration
Matching PlaceboDrug
Subcutaneous Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with a negative provocation test at week 12Time frame: From baseline to week 12
Locations
76 sites in 11 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Allervie Clinical Research
Montgomery, Alabama
One of a Kind Clinical Research Center, LLC
Paradise Valley, Arizona
Little Rock Allergy & Asthma CRC
Little Rock, Arkansas
Kern Research, Inc
Bakersfield, California
Allergy & Asthma Consultants
Redwood City, California
IMMUNOe Research Centers
Centennial, Colorado
Sarasota Clinical Research
Sarasota, Florida
Treasure Valley Medical Research
Boise, Idaho
Dawes Fretzin Dermatology Group, LLC
Indianapolis, Indiana
Allergy & Asthma Specialists, PSC
Owensboro, Kentucky
Institute for Asthma and Allergy, PC/Department of Clinical Research
Chevy Chase, Maryland
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan
University of Cincinnati
Cincinnati, Ohio
Allergy Partners of Kerrville
Kerrville, Texas
Allergy Associates of Utah
Murray, Utah
Outpatient Clinic for Individual Practice for Specialized Outpatient
Razgrad, Bulgaria
Medical Center Iskar- EOOD Office of Clinical Allergology
Sofia, Bulgaria
"Medical Center Ekselsior" OOD
Sofia, Bulgaria
"University Multiprofile Hospital for Active Treatment 'Aleksandrovska" EAD, Clinic of Clinical Allergology
Sofia, Bulgaria
Medical Center "SYNEXUS SOFIA", EOOD
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment "Prof. Dr. Stoyan Kirkovich" AD
Stara Zagora, Bulgaria
Vahlberg & Pild Clinic
Tallinn, Estonia
East Tallin Central Hospital
Tallinn, Estonia
High Technology Hospital Medcenter
Batumi, Georgia
Healthy Future
Tbilisi, Georgia
Center of Allergy and Immunology
Tbilisi, Georgia
Multiprofile Clinic Consilium Medulla
Tbilisi, Georgia
Institute of Allergology IFA
Berlin, Germany
Universitätsklinikum Heidelberg - Dermatologie
Heidelberg, Germany
Universitätsklinikum Augsburg
Augsburg, Bavaria, Germany
LMU Klinikum - Klinik und Poliklinik für Dermatologie und Allergologie DASZ-Dermato-Allergologisches Studien Zentrum
München, Bavaria, Germany
Universitaetsklinikum Giessen u. Marburg GmbH
Marburg, Hesse, Germany
Elbe Klinikum Buxtehude
Buxtehude, Lower Saxony, Germany
Hannover Medical University
Hanover, Lower Saxony, Germany
Klinikum Oldenburg gGmbH - Klinik f. Dermatologie u. Allergologie
Oldenburg, Lower Saxony, Germany
Universitätsklinikum Düsseldorf - Dermatologie
Düsseldorf, North Rhine-Westphalia, Germany
Universitätsklinikum Essen Klinikum f. Dermatologie, Venerologie u. Allergologie Hufelandstr
Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Münster Klinik u. Poliklinik f. Dermatologie
Münster, North Rhine-Westphalia, Germany
Universitätsklinikum Dresden
Dresden, Saxony, Germany
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.